Titre
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Khanna, N.
Auteure/Auteur
Opravil, M.
Auteure/Auteur
Furrer, H.
Auteure/Auteur
Cavassini, M.
Auteure/Auteur
Vernazza, P.
Auteure/Auteur
Bernasconi, E.
Auteure/Auteur
Weber, R.
Auteure/Auteur
Hirschel, B.
Auteure/Auteur
Battegay, M.
Auteure/Auteur
Kaufmann, G.R.
Auteure/Auteur
Contributrices/contributeurs
Battegay, M.
Bernasconi, E.
Böni, J.
Bucher, HC.
Bürgisser, P.
Calmy, A.
Cattacin, S.
Cavassini, M.
Dubs, R.
Egger, M.
Elzi, L.
Erb, P.
Fischer, M.
Flepp, M.
Fontana, A.
Francioli, P.
Furrer, H.
Fux, C.
Gorgievski, M.
Günthard, H.
Hirsch, H.
Hirschel, B.
Hösli, I.
Kahlert, C.
Kaiser, L.
Karrer, U.
Kind, C.
Klimkait, T.
Ledergerber, B.
Martinetti, G.
Martinez, B.
Müller, N.
Nadal, D.
Opravil, M.
Paccaud, F.
Pantaleo, G.
Rauch, A.
Regenass, S.
Rickenbach, M.
Rudin, C.
Schmid, P.
Schultze, D.
Schüpbach, J.
Speck, R.
Taffé, P.
Tarr, P.
Telenti, A.
Trkola, A.
Vernazza, P.
Weber, R.
Yerly, S.
Groupes de travail
Swiss HIV Cohort Study
Liens vers les personnes
Liens vers les unités
ISSN
1537-6591
Statut éditorial
Publié
Date de publication
2008-10
Volume
47
Numéro
8
Première page
1093
Dernière page/numéro d’article
1101
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on immunological recovery remains uncertain.
METHODS: During January 1996 through December 2004 [corrected] all patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values (n = 3293). For follow-up, we used the Swiss HIV Cohort Study database update of May 2007 [corrected] The mean (+/-SD) duration of follow-up was 26.8 +/- 20.5 months. The follow-up time was limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell count in the 3 treatment groups after the initiation of cART.
RESULTS: Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220 to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count.
CONCLUSION: CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and boosted PI-based cART.
METHODS: During January 1996 through December 2004 [corrected] all patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values (n = 3293). For follow-up, we used the Swiss HIV Cohort Study database update of May 2007 [corrected] The mean (+/-SD) duration of follow-up was 26.8 +/- 20.5 months. The follow-up time was limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell count in the 3 treatment groups after the initiation of cART.
RESULTS: Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220 to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count.
CONCLUSION: CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and boosted PI-based cART.
PID Serval
serval:BIB_2C6AC06C2B04
PMID
Open Access
Oui
Date de création
2009-03-06T07:23:53.263Z
Date de création dans IRIS
2025-05-20T19:41:34Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
REF.pdf
Version du manuscrit
published
Taille
661.78 KB
Format
Adobe PDF
PID Serval
serval:BIB_2C6AC06C2B04.P001
URN
urn:nbn:ch:serval-BIB_2C6AC06C2B044
Somme de contrôle
(MD5):20ab80a620f775b4fef96d75e281886b